京新药业
(002020)
| 流通市值：97.81亿 | | | 总市值：116.33亿 |
| 流通股本：7.24亿 | | | 总股本：8.61亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 956,068,676.24 | 4,158,550,673.09 | 3,208,743,897.71 | 2,149,921,275.37 |
| 营业收入 | 956,068,676.24 | 4,158,550,673.09 | 3,208,743,897.71 | 2,149,921,275.37 |
| 二、营业总成本 | 785,814,459.84 | 3,369,944,245.48 | 2,608,110,283.39 | 1,735,633,089.02 |
| 营业成本 | 499,884,956.64 | 2,080,348,271.39 | 1,568,830,620.06 | 1,041,122,206.89 |
| 税金及附加 | 10,089,945.51 | 49,874,605.96 | 34,319,963.51 | 22,617,821.03 |
| 销售费用 | 151,399,189.96 | 692,264,053.54 | 587,603,792.33 | 383,812,173.66 |
| 管理费用 | 49,540,340.73 | 228,406,263.97 | 194,483,465.65 | 127,714,184.38 |
| 研发费用 | 87,331,667.77 | 383,484,629.45 | 269,444,316.12 | 197,024,431.93 |
| 财务费用 | -12,431,640.77 | -64,433,578.83 | -46,571,874.28 | -36,657,728.87 |
| 其中:利息费用 | 1,723,714.7 | 7,742,952.12 | 7,258,253.21 | 6,094,129.7 |
| 其中:利息收入 | 14,723,102.5 | 71,239,015.11 | 57,501,060.04 | 41,610,562.03 |
| 加:公允价值变动收益 | 67,808.22 | -42,367,026.33 | 894,143.84 | 853,424.66 |
| 加:投资收益 | 4,406,931.9 | 8,957,002.94 | 5,969,548.08 | -132,060.33 |
| 资产处置收益 | -87,980.17 | 2,587,796.61 | 346,885.05 | 239,398.95 |
| 资产减值损失(新) | 5,076,268.62 | -12,807,871.28 | 101,627.74 | 1,409,155.4 |
| 信用减值损失(新) | -1,929,216.34 | -14,574,385.49 | -17,634,106.9 | -12,617,473.37 |
| 其他收益 | 15,406,145.97 | 113,204,051.14 | 81,503,553.5 | 72,130,233.36 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 193,194,174.6 | 843,605,995.2 | 671,815,265.63 | 476,170,865.02 |
| 加:营业外收入 | 556,055.24 | 4,611,460.66 | 7,571,629.08 | 4,707,447.17 |
| 减:营业外支出 | 534,290.53 | 4,237,580.21 | 2,922,596.43 | 756,402.16 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 193,215,939.31 | 843,979,875.65 | 676,464,298.28 | 480,121,910.03 |
| 减:所得税费用 | 27,834,638.39 | 124,853,763.99 | 95,904,869.65 | 74,251,591.08 |
| 六、净利润 | 165,381,300.92 | 719,126,111.66 | 580,559,428.63 | 405,870,318.95 |
| 持续经营净利润 | 165,381,300.92 | 719,126,111.66 | 580,559,428.63 | 405,870,318.95 |
| 归属于母公司股东的净利润 | 163,292,650.63 | 711,961,458.77 | 575,012,790.33 | 402,122,680.69 |
| 少数股东损益 | 2,088,650.29 | 7,164,652.89 | 5,546,638.3 | 3,747,638.26 |
| (一)基本每股收益 | 0.2 | 0.83 | 0.67 | 0.47 |
| (二)稀释每股收益 | 0.2 | 0.83 | 0.67 | 0.47 |
| 八、其他综合收益 | -93,589.79 | 709,602.25 | 206,930.55 | 385,583.07 |
| 归属于母公司股东的其他综合收益 | -90,985.41 | 695,172.61 | 206,537.51 | 381,592.86 |
| 九、综合收益总额 | 165,287,711.13 | 719,835,713.91 | 580,766,359.18 | 406,255,902.02 |
| 归属于母公司股东的综合收益总额 | 163,201,665.22 | 712,656,631.38 | 575,219,327.84 | 402,504,273.55 |
| 归属于少数股东的综合收益总额 | 2,086,045.91 | 7,179,082.53 | 5,547,031.34 | 3,751,628.47 |
| 公告日期 | 2025-04-28 | 2025-04-03 | 2024-10-25 | 2024-08-15 |
| 审计意见(境内) | | 标准无保留意见 | | |